Ticker Map | Clear Almanac 89

Command readout

Price is an output, not an exposure category.

Public-market references to ibogaine can join together drug development, natural-product supply, treatment businesses, and broader psychedelic activity. This page separates those paths before any ticker is treated as relevant.

>_ QUERY: company-specific ibogaine exposure / verified public record

Public names PBM and OPTH/OPTI are commonly cited starting points. Verify current listing records

Evidence gate Filings, company releases, and trial registries carry different weight. Source hierarchy applied

Confidence rule Unclear or historic references stay provisional until upgraded by a primary record. Uncertainty retained

Exposure workflow

Company-by-company map

Last checked: October 9, 2026. These entries are context markers, not price targets, recommendations, or evidence that a company currently has a commercially viable ibogaine product.

01 / Public issuers

PBM / NASDAQ

Psyence BioMed

Category: direct drug developer Checked: 2026-10-09

Nature of exposure: Psyence BioMed has publicly described a psychedelic-drug development focus. Any ibogaine-specific exposure should be tied to the company’s current program disclosures rather than inferred from a broad psychedelic classification.

Evidence to inspect: the issuer’s current SEC filings and investor releases, alongside any study record in ClinicalTrials.gov’s searchable clinical-study database. These records can show whether a named candidate, indication, and trial status are actually documented.

Material caveat: a listed biotech can have multiple programs, changing priorities, financing needs, and limited liquidity. An ibogaine reference alone does not establish a pure-play valuation.

OPTH / OPTI / CSE references

Optimi Health

Category: botanical supplier / psychedelic-adjacent Checked: 2026-10-09

Nature of exposure: Optimi Health has been associated in public materials with natural psychedelic products and supply-related activity. That is distinct from proving a direct ibogaine-drug-development program or a treatment-provider business.

Evidence to inspect: current exchange profile information, audited financial statements, material-change reports, and company statements that specifically identify ibogaine, iboga, or related supply activity. The SEC’s EDGAR company filing search illustrates the kind of primary-record review needed for SEC-reporting issuers; Canadian-listed companies may disclose through different official channels.

Material caveat: ticker symbols and listings can change. Supply claims also require scrutiny for lawful sourcing, permits, product form, and whether any activity is material to the issuer.

Landscape view accompanying the review of ibogaine-sector evidence and company classifications

02 / Adjacent and private activity

Do not turn a name into a ticker.

Notable treatment providers, research groups, suppliers, and advocacy organizations may be relevant to the sector but may not offer public equity exposure. A private operator is not a listed security, and a public company discussing psychedelics is not automatically an ibogaine company.

The legal setting also matters. The U.S. Drug Enforcement Administration’s controlled-substances schedule reference is a useful starting point for checking federal scheduling context, while other jurisdictions can follow different rules. Regulatory status is not a substitute for a company filing.

For a broader framing of terminology and company-specific context, the sector overview provides the starting vocabulary, while the site’s research scope explains the distinction between documented signals and speculative ones.

03 / Interpretation protocol

Track the evidence behind the movement.

“Ibogaine stock price” is most useful as a search phrase when it leads back to a checkable issuer event. It is not a sector index, a clinical conclusion, or a substitute for understanding a company’s capital structure.

Verification order

First, identify the exact legal issuer and its current ticker. Second, locate the latest filing or official company release that names the exposure. Third, determine whether the activity is development, supply, treatment, or merely adjacent research. Fourth, read for qualifications: development-stage risk, planned rather than completed work, cash requirements, regulatory limits, and any absence of material revenue.

“A sector label should never carry more weight than the underlying company record.”

Clinical language deserves the same care. The U.S. Food and Drug Administration explains that an Investigational New Drug application is part of a development pathway; it does not by itself establish approval, efficacy, availability, or a future commercial outcome.

Where a source says “ibogaine,” confirm what it means: the naturally occurring alkaloid, a derivative, a preclinical concept, an announced partnership, or a service line. The general reference description of ibogaine can orient terminology, but company-specific claims should remain anchored in primary documents.

Operational questions

Map limits and practical checks

The goal is disciplined comparison, not a definitive investable universe. Names, listings, programs, and disclosures can change after the date shown above.

Is there an ibogaine pure-play stock?

The public records summarized here do not establish a clean, broad-market pure-play category. Exposure should be checked against current filings, trial records, financing disclosures, and operating updates.

Why can a ticker move without a change in ibogaine development?

Small public issuers can be affected by financing, listing status, corporate actions, changing business focus, and general market liquidity. A price move alone does not identify an ibogaine-specific cause.

What record would upgrade an uncertain entry?

A dated filing, an official company release with specific operating detail, a registered study entry, or a regulator’s record can raise confidence. Unsourced promotional language cannot.

Where does supply-chain risk enter the map?

Botanical sourcing can involve legal, geographic, processing, and documentation questions. A supplier reference should be assessed separately from clinical development or treatment activity.